Background WHO is developing a global strategy towards eliminating cervical cancer as a public health problem, which proposes an elimination threshold of four cases per 100 000 women and includes 2030 triple-intervention coverage targets for scale-up of human papillomavirus (HPV) vaccination to 90%, twice-lifetime cervical screening to 70%, and treatment of pre-invasive lesions and invasive cancer to 90%. We assessed the impact of achieving the 90-70-90 tripleintervention targets on cervical cancer mortality and deaths averted over the next century. We also assessed the potential for the elimination initiative to support target 3.4 of the UN Sustainable Development Goals (SDGs)-a one-third reduction in premature mortality from non-communicable diseases by 2030.
MethodsThe WHO Cervical Cancer Elimination Modelling Consortium (CCEMC) involves three independent, dynamic models of HPV infection, cervical carcinogenesis, screening, and precancer and invasive cancer treatment. Reductions in age-standardised rates of cervical cancer mortality in 78 low-income and lower-middle-income countries (LMICs) were estimated for three core scenarios: girls-only vaccination at age 9 years with catch-up for girls aged 10-14 years; girls-only vaccination plus once-lifetime screening and cancer treatment scale-up; and girls-only vaccination plus twice-lifetime screening and cancer treatment scale-up. Vaccination was assumed to provide 100% lifetime protection against infections with HPV types 16, 18, 31, 33, 45, 52, and 58, and to scale up to 90% coverage in 2020. Cervical screening involved HPV testing at age 35 years, or at ages 35 years and 45 years, with scale-up to 45% coverage by 2023, 70% by 2030, and 90% by 2045, and we assumed that 50% of women with invasive cervical cancer would receive appropriate surgery, radiotherapy, and chemotherapy by 2023, which would increase to 90% by 2030. We summarised results using the median (range) of model predictions.Findings In 2020, the estimated cervical cancer mortality rate across all 78 LMICs was 13•2 (range 12•9-14•1) per 100 000 women. Compared to the status quo, by 2030, vaccination alone would have minimal impact on cervical cancer mortality, leading to a 0•1% (0•1-0•5) reduction, but additionally scaling up twice-lifetime screening and cancer treatment would reduce mortality by 34•2% (23•3-37•8), averting 300 000 (300 000-400 000) deaths by 2030 (with similar results for once-lifetime screening). By 2070, scaling up vaccination alone would reduce mortality by 61•7% (61•4-66•1), averting 4•8 million (4•1-4•8) deaths. By 2070, additionally scaling up screening and cancer treatment would reduce mortality by 88•9% (84•0-89•3), averting 13•3 million (13•1-13•6) deaths (with once-lifetime screening), or by 92•3% (88•4-93•0), averting 14•6 million (14•1-14•6) deaths (with twice-lifetime screening). By 2120, vaccination alone would reduce mortality by 89•5% (86•6-89•9), averting 45•8 million (44•7-46•4) deaths. By 2120, additionally scaling up screening and cancer treatment would reduce m...
